WitrynaNaki is developing car-NK therapeutics, based on their own NK cell expansion platform, which will be used for the treatment of solid tumors. Links. About us Portfolio Team … Witryna他 在细胞治疗领域拥有近20年的研发管理、质量研究、工艺开发等方面的经验，回国前曾担任美国圣地亚哥Sorrento Therapeutics公司细胞治疗科学家、基因和细胞治疗公司Precigen的项目负责人，及NAKI Therapeutics的研发副总裁。

NAKI Therapeutics VentureRadar

Witryna12 kwi 2024 · Today, I’m excited to announce Project Health Insights Preview. Project Health Insights is a service that derives insights based on patient data and includes pre-built models that aim to power key high value scenarios in the health domain. The models receive patient data in different modalities, perform analysis, and enable clinicians to … Witryna11 kwi 2024 · Captor Therapeutics odnotował 35,89 mln zł skonsolidowanej straty netto przypisanej akcjonariuszom jednostki dominującej w 2024 r. wobec 32,57 mln zł straty rok wcześniej, podała spółka. Strata operacyjna wyniosła 38,36 mln zł wobec 31,71 mln zł straty rok wcześniej. Skonsolidowane przychody ze sprzedaży sięgnęły 9,16 mln zł … new ming chinese san francisco

Naki Therapeutics Viva BioInnovator

http://nikangtx.com/ WitrynaNAKI Therapeutics is an innovative research-focused biopharmaceutical company. Our core technology is surrounding Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy with ground-breaking allogeneic or ‘off-the-shelf’ expansion technology and a ‘first-in-class’ solid tumor molecular target-CD147. WitrynaNAKI Therapeutics. Private Company. Founded 2024. USA. NAKI Therapeutics is an innovative research-focused biopharmaceutical company. Our core technology is surrounding Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy with ground-breaking allogeneic or ‘off-the-shelf’ expansion... new ming garden menu isle of wight